Navigation Links
AstraZeneca Medicare Part D Patient Assistance Program No Longer Requires Co-Pays
Date:12/8/2009

WILMINGTON, Del., Dec. 8 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) announced today that patients enrolled in the company's Medicare Part D prescription savings program will no longer pay co-pays for their medicines through the program.

(Logo: http://www.newscom.com/cgi-bin/prnh/20091027/PH99766LOGO )

Prescriptions also now will be mailed to patients' homes or physician's offices under the changes to the AZ&Me(TM) Prescription Savings program for people with Medicare Part D. The changes will take effect Jan. 1, 2010.

"These changes will better serve Medicare Part D enrollees by making it easier for them to access the medicines they need," said Rich Fante, US President, AstraZeneca Pharmaceuticals LP. "This prescription savings program and these latest improvements reflect our ongoing commitment to patient health."

Currently, patients enrolled in the program fill their AstraZeneca prescriptions at retail pharmacies and have a co-pay of between $15 and $25, depending on their qualifying income. The elimination of a co-pay will save approximately 30,000 patients enrolled in the program a total of $3 million each year.

Program Details

Eligible patients can enroll in the AZ&Me(TM) Prescription Savings program for people with Medicare Part D at any time in the calendar year, but must meet program requirements in order to start utilizing the benefit.

The AZ&Me(TM) Prescription Savings program for people with Medicare Part D is one of three distinct prescription savings programs in the AZ&Me Prescription Savings Program suite. Other AZ&Me Prescription Savings Programs include a plan for individuals without insurance and one for healthcare facilities.

To learn if you qualify for the AZ&Me Prescription Savings Programs, please visit www.AZandMe.com or call 1-800-AZandMe. Program specialists are available Monday through Friday between the hours of 9:00 AM and 5:00 PM EST.

Other prescription savings programs are available regardless of which medications your doctors prescribe. To find out more about the more than 475 savings programs covering 2,500 medications, please visit www.pparx.org or call 1-888-4PPA-NOW (1-888-477-2669).

NOTES TO EDITORS:

About AstraZeneca

AstraZeneca is engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and in the supply of healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with global healthcare sales of $31.6 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines. In the United States, AstraZeneca is a $13.5 billion healthcare business.

For more information about AstraZeneca in the US or our AZ&Me(TM) Prescription Savings programs, please visit: www.astrazeneca-us.com.

SOURCE AstraZeneca


'/>"/>
SOURCE AstraZeneca
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. U.S. Court of Appeals Upholds AstraZeneca AWP Settlement
2. Emerging Agents from Theravance/Astellas, Johnson & Johnson/Basilea and Forest/Astrazeneca/Takeda Will Drive Modest Growth in the MRSA Drug Market Through 2018
3. Dr. Steven M. Paul to Retire from Lilly as Executive Vice President, Science and Technology, President, Lilly Research Laboratories; Dr. Jan M. Lundberg, Executive Vice President, Head of Global Discovery Research, AstraZeneca, Named his Successor
4. Jubilant Enters Research Collaboration With AstraZeneca
5. AstraZeneca Submits NDA for Low Dose Aspirin/Esomeprazole Combination Product
6. AstraZenecas Partner, MAP Pharmaceuticals, Announces Phase 3 Study of Unit Dose Budesonide in Children with Asthma Did Not Meet Primary Endpoints
7. AstraZeneca Responds to FDA Joint Advisory Committees Recommendation on SYMBICORT(R)
8. AstraZeneca and Targacept Announce Top-Line Results from Phase IIb Study of AZD3480 in Cognitive Dysfunction in Schizophrenia
9. AstraZeneca Receives Six Months Pediatric Exclusivity for CASODEX(R) (bicalutamide) from the FDA
10. AstraZeneca and Targacept Announce Top-Line Results from Phase IIb Study of AZD3480 in Alzheimers Disease
11. AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... SOUTH SAN FRANCISCO, Calif. , June 24, ... GBT ), a biopharmaceutical company developing novel ... with significant unmet needs, today announced the closing ... 6,400,000 shares of common stock, at the public ... the shares in the offering were offered by ...
(Date:6/24/2016)... Dublin ... of the " Global Markets for Spectroscopy Equipment" ... This report focuses on the global ... including its applications in various applications. The report deals ... three main industries: pharmaceutical and biotechnology, food and beverage, ...
(Date:6/24/2016)... Va. , June 24, 2016 The ... set of recommendations that would allow biopharmaceutical ... (HCEI) with entities that make formulary and coverage decisions, ... the "value" of new medicines. The recommendations ... does not appear on the drug label, a prohibition ...
Breaking Medicine Technology:
(Date:6/26/2016)... Lake Orion, Clarkston, Michigan (PRWEB) , ... June ... ... direction with respect to fertility once they have been diagnosed with endometriosis. These ... tolerable intercourse but they also require a comprehensive approach that can help for ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... First ... United States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell ... facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, ... Elite. The attorneys chosen by their peers for this recognition are considered among the ... Traurig Shareholders received special honors as members of this year’s Legal Elite Hall of ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB ... Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards ... in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With ...
Breaking Medicine News(10 mins):